EANS-Adhoc: LifeWatch announces comprehensive cardiac monitoring suite in a technology breakthrough using a single device platform (with document)

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

New Products/LifeWatch AG

08.03.2012

Neuhausen am Rheinfall/Switzerland - In an industry first and
exclusive development, LifeWatch AG (SIX Swiss Exchange:LIFE), a
leading wireless monitoring and technology company in the U.S., has
announced a comprehensive cardiac monitoring suite embodied in a
single technology platform. This software defined medical device
encompasses the capabilities of Holter, CEM (auto trigger/auto send
and patient activation) as well as the Company's leading and
proprietary ACT Ambulatory Cardiac Telemetry product and service. The
Company has conducted and concluded a regulatory review to assure
compliance with FDA regulations on this cleared medical device with
the proper indications for use.

You will find a PDF-version of this press release at the end of this
message.

"The Elite service addresses many of the significant needs identified
to LifeWatch by our users over a several year period of time. It is
an acknowledgement to these customers that we have listened to their
concerns and issues and according to them, responded appropriately to
their needs," stated Dr. Yacov Geva, Chairman and CEO of LifeWatch
AG, "The Elite service is arguably the most sophisticated outpatient
cardiac monitoring service and technology in the market today".

A programmable feature switches the device from the advanced ACT III
ambulatory ECG telemetry system (with 3-channel ECG and optional
24-48 hour Holter reporting), to a sophisticated Auto-
Detect/Auto-Send 3-channel ECG cardiac monitoring system. This
state-of-the-art technology also enables a streamlined enrollment
process, better and easier onsite inventory control for customers
and delivers additional customer efficiencies by eliminating the
confusing panoply of inconsistent service and technology choices
faced by physicians in busy practices.

The Elite service builds on LifeWatch's already fielded ACT Ex
extended service which allows a physician to order a Holter test
prior to determining the need for the ACT Telemetry service. The ACT
Ex has improved patient compliance as the patient can seamlessly
transition from Holter to ambulatory cardiac telemetry if, after 48
hours of monitoring, there has not been a diagnostic finding and the
physician wishes to have the patient monitored for an extended period
of time without having to come back to the office and switch out
devices.

The addition of the auto trigger/auto send capability of a cardiac
event monitor to the ACT platform, closes the loop for the physician
by adding this capability to his diagnostic arsenal. If the patient
leaves the office with the ACT service and it is discovered, for
instance, that the patient didn't meet the criteria for the ACT
service, instead of contacting the patient and having them return to
the practice to get fitted with another device, a software change is
made transparently to the patient and the service now becomes an auto
trigger/auto send CEM service. The Elite service makes simplicity an
attribute of the present market situation and allows the physician to
concentrate on practicing medicine without worrying about monitoring.

It is estimated that approximately 70% of present LifeWatch customers
will benefit from this additional capability.

About LifeWatch AG:

LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on
SIX Swiss Exchange (LIFE), Switzerland, is the leading healthcare
technology and solution company, specializing in advanced telehealth
systems and wireless remote patient monitoring services. LifeWatch
services cater to individuals, ranging from high-risk and chronically
ill patients, to consumers of health and wellness products. LifeWatch
has subsidiaries in the United States, the Netherlands, Japan, the
United Kingdom, Switzerland and Israel. LifeWatch AG is the parent
company of LifeWatch Services Inc., a leading US-based cardiac
monitoring service provider, and manufacturer of telecardiology
products. LifeWatch is also introducing a new program for Home Sleep
Testing of Obstructive Sleep Apnea (OSA) patients under the brand
name NiteWatch. For additional information, please visit
www.lifewatch.com.

Sign-up for customized E-mail alerts and documentation requests is
available at http://production.investis.com/lifewatch/alert-service/

This press release includes forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding future results of
operations and financial position, business strategy and plans and
objectives for future operations, are forward-looking statements. The
words "believe," "may," "will," "estimate," "continue," "anticipate,"
"intend," "expect" and similar expressions are intended to identify
forward-looking statements. LifeWatch AG has based these
forward-looking statements largely on current expectations and
projections about future events and financial trends that it believes
may affect the financial condition, results of operations, business
strategy, short term and long term business operations and
objectives, and financial needs. These forward-looking statements are
subject to a number of risks, uncertainties and assumptions. In light
of these risks, uncertainties and assumptions, the forward-looking
events and circumstances described may not occur and actual results
could differ materially and adversely from those anticipated or
implied in the forward-looking statements. All forward-looking
statements are based only on data available to LifeWatch AG at the
time of the issue of this press release. LifeWatch AG does not
undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information,
future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF
AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR
PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS
PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH
AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED STATES OR AN
INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF LIFEWATCH
AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE
SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN
REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE
OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S.
PERSONS ABSENT REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE
REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS. ANY
PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE
MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH AG
OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED
INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL
STATEMENTS OF THE ISSUER.

Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/Rd8E7zsy

Further inquiry note:
Sensus Investor and Public Relations, Zürich:
Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | Email lifewatch@sensus.ch

end of announcement euro adhoc
--------------------------------------------------------------------------------

Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/Rd8E7zsy

issuer: LifeWatch AG
Rundbuckstrasse 6
CH-8212 Neuhausen am Rheinfall
phone: +41 52 632 00 50
FAX: +41 52 632 00 51
mail: users@lifewatch.com
WWW: www.lifewatch.com
sector: Healthcare Providers
ISIN: CH0012815459
indexes: SPI, SPIEX
stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard:
SIX Swiss Exchange
language: English